Best Stocks Under $3 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $3.00 (3 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Denison Mines NYSEAMERICAN:DNN$1.58 -0.01 (-0.32%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.42 billionP/E Ratio-158.30Consensus RatingStrong BuyConsensus Price Target$3.00 (+90.5% Upside)Volume7.21 million sharesAverage Volume39.92 million shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Mereo BioPharma Group NASDAQ:MREO$2.82 -0.05 (-1.60%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$437.21 millionConsensus RatingBuyConsensus Price Target$7.83 (+177.4% Upside)Volume41,283 sharesAverage Volume1.11 million sharesToday's Range$2.83▼$2.903. enCore Energy NASDAQ:EU$2.68 -0.06 (-2.01%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore EnergyMarket Capitalization$501.59 millionP/E Ratio-9.62Consensus RatingBuyConsensus Price Target$6.50 (+142.1% Upside)Volume184,351 sharesAverage Volume1.51 million shares4. Quince Therapeutics NASDAQ:QNCX$1.42 -0.03 (-2.07%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$62.48 millionP/E Ratio-1.15Consensus RatingBuyConsensus Price Target$9.50 (+569.0% Upside)Volume15,230 sharesAverage Volume126,808 shares5. Cardiol Therapeutics NASDAQ:CRDL$1.25 -0.05 (-3.46%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$103.68 millionP/E Ratio-3.22Consensus RatingBuyConsensus Price Target$8.40 (+569.3% Upside)Volume28,084 sharesAverage Volume258,619 shares6. Nkarta NASDAQ:NKTX$2.08 -0.07 (-3.02%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$147.14 millionP/E Ratio-1.11Consensus RatingBuyConsensus Price Target$15.00 (+619.4% Upside)Volume141,930 sharesAverage Volume1.00 million shares7. Aclaris Therapeutics NASDAQ:ACRS$2.28 -0.03 (-1.39%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$162.58 millionP/E Ratio-4.38Consensus RatingBuyConsensus Price Target$11.00 (+382.9% Upside)Volume62,020 sharesAverage Volume783,220 shares8. GeoVax Labs NASDAQ:GOVX$1.62 -0.01 (-0.48%) As of 10:19 AM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$15.31 millionConsensus RatingBuyConsensus Price Target$14.20 (+775.4% Upside)Volume29,278 sharesAverage Volume546,184 sharesToday's Range$1.62▼$1.699. Reviva Pharmaceuticals NASDAQ:RVPH$1.64 +0.01 (+0.31%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$54.67 millionP/E Ratio-1.47Consensus RatingBuyConsensus Price Target$11.40 (+597.2% Upside)Volume120,599 sharesAverage Volume1.97 million shares10. Rezolve AI NASDAQ:RZLV$2.66 +0.09 (+3.29%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolve Ai Ltd. operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. More about Rezolve AIMarket Capitalization$460.58 millionConsensus RatingBuyConsensus Price Target$6.40 (+140.2% Upside)Volume1.51 million sharesAverage Volume7.97 million sharesToday's Range$2.63▼$2.7311. Immunic NASDAQ:IMUX$1.34 +0.17 (+13.98%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$121.16 millionP/E Ratio-1.09Consensus RatingBuyConsensus Price Target$12.67 (+841.8% Upside)Volume737,877 sharesAverage Volume956,226 shares12. HIVE Digital Technologies NASDAQ:HIVE$2.65 -0.04 (-1.64%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$415.80 millionP/E Ratio-53.10Consensus RatingBuyConsensus Price Target$8.08 (+205.5% Upside)Volume1.75 million sharesAverage Volume10.14 million shares13. Western Copper & Gold NYSE:WRN$1.03 -0.02 (-1.90%) As of 10:18 AM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$204.34 millionP/E Ratio-51.50Consensus RatingBuyConsensus Price Target$4.25 (+312.6% Upside)Volume67,177 sharesAverage Volume311,945 shares14. Gain Therapeutics NASDAQ:GANX$2.30 -0.05 (-1.92%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$60.89 millionP/E Ratio-2.09Consensus RatingBuyConsensus Price Target$7.25 (+215.9% Upside)Volume12,710 sharesAverage Volume214,409 shares15. PMV Pharmaceuticals NASDAQ:PMVP$1.42 +0.01 (+0.35%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. More about PMV PharmaceuticalsMarket Capitalization$73.74 millionP/E Ratio-1.43Consensus RatingBuyConsensus Price Target$5.50 (+286.0% Upside)Volume44,666 sharesAverage Volume142,104 shares16. Lucid Diagnostics NASDAQ:LUCD$1.55 +0.06 (+4.03%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$91.98 millionP/E Ratio-1.36Consensus RatingBuyConsensus Price Target$3.63 (+133.9% Upside)Volume86,934 sharesAverage Volume468,225 shares17. Invivyd NASDAQ:IVVD$1.48 +0.27 (+22.07%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. More about InvivydMarket Capitalization$174.41 millionP/E Ratio-0.74Consensus RatingBuyConsensus Price Target$7.89 (+434.0% Upside)Volume4.47 million sharesAverage Volume24.23 million shares18. FibroBiologics NASDAQ:FBLG$1.14 -0.10 (-7.66%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$41.69 millionConsensus RatingBuyConsensus Price Target$13.00 (+1,035.4% Upside)Volume65,611 sharesAverage Volume375,646 sharesToday's Range$1.18▼$1.2519. New Gold NYSE:NGD$2.83 -0.18 (-5.95%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.New Gold Inc, an intermediate gold mining company, develops and operates of mineral properties in Canada. It primarily explores for gold, silver, and copper deposits. More about New GoldMarket Capitalization$2.23 billionP/E Ratio21.73Consensus RatingBuyConsensus Price Target$3.60 (+27.2% Upside)Volume2.29 million sharesAverage Volume12.22 million shares20. Electrovaya NASDAQ:ELVA$2.36 -0.03 (-1.21%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Electrovaya Inc engages in the design, development, manufacture, and sale of lithium-ion batteries, battery management systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications in North America. More about ElectrovayaMarket Capitalization$94.65 millionP/E Ratio-59.03Consensus RatingBuyConsensus Price Target$6.10 (+158.4% Upside)Volume7,032 sharesAverage Volume80,377 shares21. Rani Therapeutics NASDAQ:RANI$1.70 -0.04 (-2.02%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$97.11 millionP/E Ratio-1.60Consensus RatingBuyConsensus Price Target$12.33 (+627.6% Upside)Volume46,684 sharesAverage Volume1.45 million shares22. ProQR Therapeutics NASDAQ:PRQR$2.59 +0.01 (+0.39%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$211.55 millionP/E Ratio-8.09Consensus RatingBuyConsensus Price Target$8.83 (+241.1% Upside)Volume21,889 sharesAverage Volume309,293 shares23. Context Therapeutics NASDAQ:CNTX$0.80 +0.01 (+1.65%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$60.23 millionP/E Ratio-0.88Consensus RatingBuyConsensus Price Target$6.33 (+688.7% Upside)Volume12,120 sharesAverage Volume217,647 shares24. Prime Medicine NYSE:PRME$2.99 -0.14 (-4.60%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. More about Prime MedicineMarket Capitalization$391.64 millionP/E Ratio-1.46Consensus RatingBuyConsensus Price Target$13.13 (+339.6% Upside)Volume119,527 sharesAverage Volume943,864 shares25. Geron NASDAQ:GERN$2.56 -0.07 (-2.47%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. More about GeronMarket Capitalization$1.56 billionP/E Ratio-8.05Consensus RatingBuyConsensus Price Target$6.91 (+169.4% Upside)Volume1.50 million sharesAverage Volume11.56 million shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Skids—How Much Further Can It Fall? Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive SoundHound AI Stock at a Crossroads—Is a Bottom in Sight? SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It? Buffett’s Billion-Dollar Bet: Will Constellation Brands Pay Off? Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? Medtronic’s Expansion Gains Momentum—Time for a Market Shift? 3 Stocks With Robust Growth Outlooks Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
